StockNews.AI

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

StockNews.AI • 2 days

HRTX
High Materiality8/10

Information

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or th...

Original source

AI Summary

Heron Therapeutics reports Q4 2025 revenue growth driven by product sales. Total revenue for Q4 2025 is approximately $40.5 million. ZYNRELEF® revenue shows significant growth at $12.5 million. APONVIE® and CINVANTI® also contribute notable sales for the quarter. Company continues to progress in business operations, boosting investor confidence.

Sentiment Rationale

Historically, strong revenue reports, particularly from key products, tend to lead to increased stock price traction. This Q4 performance builds upon previous growth trends observed in Heron's portfolio.

Trading Thesis

Immediate market reactions to revenue milestones usually reflect quickly, particularly around earnings reports, which influence investor sentiment over the next quarterly period.

Market-Moving

  • Heron's substantial revenue growth may attract bullish sentiment among investors.
  • The 35% revenue increase for ZYNRELEF® indicates robust market demand.
  • Continued growth in Acute Care products could stabilize HRTX’s stock price.
  • Strong quarterly performance may position HRTX for positive analyst upgrades.
  • Investor confidence is likely to increase due to operational progress.

Key Facts

  • Heron Therapeutics reports Q4 2025 revenue growth driven by product sales.
  • Total revenue for Q4 2025 is approximately $40.5 million.
  • ZYNRELEF® revenue shows significant growth at $12.5 million.
  • APONVIE® and CINVANTI® also contribute notable sales for the quarter.
  • Company continues to progress in business operations, boosting investor confidence.

Companies Mentioned

  • HRTX (HRTX)

Corporate Developments

The article outlines significant revenue growth and operational gains, which directly impact HRTX’s market perception and potential stock performance.

Heron Therapeutics Reports Strong Q4 and Full-Year 2025 Revenues; ZYNRELEF® Leads Growth

CARY, N.C., January 9, 2026 (GLOBE NEWSWIRE) – Heron Therapeutics, Inc. (Nasdaq: HRTX), a leading biotechnology company, has announced its preliminary, unaudited financial results for the fourth quarter and full-year 2025. The company reported a significant upward trend in revenues, primarily driven by the performance of its Acute Care franchise, particularly ZYNRELEF® and APONVIE®.

Financial Highlights from Q4 and Full-Year 2025

Heron Therapeutics reported preliminary net revenue of approximately $40.5 million for the quarter ending December 31, 2025. The breakdown of revenue for key products is as follows:

  • ZYNRELEF®: Approximately $12.5 million
  • APONVIE®: Approximately $3.8 million
  • CINVANTI®: Approximately $22.9 million
  • SUSTOL®: Approximately $1.3 million

For the full year of 2025, Heron reported net revenue of approximately $154.9 million. Notably, ZYNRELEF® achieved a 35% quarter-over-quarter revenue increase compared to Q3 2025, underscoring its growing market momentum.

Insights from Leadership

Craig Collard, Chief Executive Officer of Heron Therapeutics, expressed optimism about the company's performance. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®. In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year,” said Collard.

Product Portfolio Overview

ZYNRELEF®

ZYNRELEF® is a groundbreaking extended-release local anesthetic that combines bupivacaine and a low dose of meloxicam. It is the first product approved to significantly reduce postoperative pain while minimizing the need for opioids. Initially approved by the FDA in May 2021, ZYNRELEF® has expanded indications to several surgical procedures, demonstrating its vital role in postoperative care.

APONVIE®

APONVIE® is designed to prevent postoperative nausea and vomiting (PONV) in adults. Delivered rapidly via IV push, it provides an effective alternative to oral medication. Following its FDA approval in September 2022, APONVIE® became available in the U.S. on March 6, 2023.

CINVANTI®

Targeting the management of nausea and vomiting associated with chemotherapy, CINVANTI® is the first IV formulation of aprepitant, effective in combating both acute and delayed symptoms linked to emetogenic cancer treatments.

SUSTOL®

SUSTOL® is utilized in conjunction with other antiemetics to prevent nausea and vomiting from moderately emetogenic chemotherapy. With its innovative drug delivery technology, it maintains therapeutic levels for an extended period, demonstrating durable efficacy in cancer patients.

Company Overview

Heron Therapeutics, Inc. is committed to enhancing patient care through the development and commercialization of innovative therapeutics. The company's product portfolio is designed to advance healthcare standards for acute care and oncology patients. To learn more, visit www.herontx.com.

Forward-Looking Statements

This release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements reflect the company’s expectations and are subject to known and unknown risks that could cause actual results to differ materially.

Related News